Media Room

Latest News Releases

Jul 18, 2017

Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain

Nektar Therapeutics (NASDAQ: NKTR) announced positive topline results from an oral Human Abuse Potential (HAP) study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical...

Jul 10, 2017

Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London

Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune disease. The new preclinical data demonstrate...

Jun 6, 2017

Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June...

Multimedia Libraries

Broadcast Video

Image Gallery

Media Contacts

Dan Budwick
Pure Communications, Inc.
Media@purecommunications...

Follow @NektarNews

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide